Inclusion Criteria:

- Histologic or cytologic diagnosis (recent or remote) of metastatic renal cell
carcinoma (including papillary, clear cell, and excluding transitional cell types)
that is not amendable to cure by surgery or other means, and must have failed at
least one prior systemic therapy, including but not limited to treatment with
sunitinib, temsirolimus or sorafenib

- Evaluable/Measureable disease according to Response Criteria for Solid tumors

- Eastern Cooperative Group performance status of 0-1

- Therapeutic anti-coagulation (PT, and/or INR, PTT) permitted, if clinically stable
and >/= 3 months from initiation

Exclusion Criteria:

- Past or present documented central nervous system (CNS) tumor or CNS metastasis

- Use of investigational drug (including marketed drugs not approved for this
indication) within 4 weeks prior to screening or 5 half-lives of the prior
investigational drug (whichever is longer)

- History of thromboembolic events and bleeding disorders PE)

- Major Surgery (that requires general anesthesia) within 4 weeks of study enrollment